Beyond the Sneeze: A Novel RNA Vaccine Enters Trials for Japan's Allergy Crisis

ROCKVILLE, MD – July 02, 2026 – In a move that could reshape the future of allergy treatment, Immunomic Therapeutics Inc. (ITI), a subsidiary of South Korea's HLB Group, has dosed the first participant in a Phase 1 clinical trial for its investigational vaccine, ITI-9001. The target is one of modern medicine’s most widespread and stubborn adversaries: Japanese cedar pollen allergy. The trial's launch in Japan, less than a month after receiving regulatory clearance, signals a significant acceleration in the quest for a more durable solution to a condition that plagues nearly 40% of the nation's population.

While allergy sufferers are accustomed to a cycle of temporary fixes, ITI-9001 represents a fundamentally different strategy. By leveraging a sophisticated combination of proprietary technologies, the company isn't just aiming to mask symptoms—it's trying to retrain the immune system at a cellular level. The initiation of human trials marks a critical inflection point, moving this next-generation immunotherapy from the laboratory into the real world.

A 'National Disease' Seeks a Modern Cure

In Japan, Japanese cedar pollen allergy, or "Kafunsho," is more than a seasonal nuisance; it's a public health crisis. Affecting an estimated 48 million people, its impact ripples through the economy and society. The annual onslaught of sneezing, nasal congestion, and itchy eyes degrades quality of life, hampers productivity, and burdens the healthcare system. The problem is so pervasive that the Japanese government has officially labeled it a "social problem" and a "national disease," vowing to prioritize measures to combat it.

For decades, the standard of care has been a two-pronged approach: symptomatic relief and allergen immunotherapy (AIT). Over-the-counter and prescription antihistamines, steroid sprays, and eye drops offer temporary respite but do nothing to alter the underlying allergic response. AIT, which includes subcutaneous injections (SCIT) or sublingual tablets (SLIT), aims for a more lasting effect by gradually exposing the body to the allergen. While SLIT, approved in Japan since 2014, offers the convenience of at-home administration, both forms of traditional immunotherapy are demanding, often requiring daily adherence over three to five years to achieve a durable benefit. This long-term commitment leads to significant challenges with patient compliance and satisfaction.

This landscape creates a vast unmet need for a more efficient, powerful, and lasting treatment. The market is primed for an innovation that can offer the disease-modifying benefits of immunotherapy without the burdensome treatment schedules, a gap that Immunomic Therapeutics believes ITI-9001 is uniquely positioned to fill.

Rewriting the Immune Response with RNA and UNITE®

The scientific foundation of ITI-9001 is where its revolutionary potential truly lies. The vaccine candidate combines two powerful technologies: ITI's proprietary UNITE® platform and self-amplifying RNA (saRNA).

The UNITE® (Universal Intracellular Targeted Expression) platform is engineered to enhance how the body's immune system 'sees' an allergen. It works by fusing the target antigen—in this case, CryJ2, a major allergen from Japanese cedar pollen—with a human protein called LAMP-1 (Lysosomal Associated Membrane Protein). This molecular fusion acts like a GPS, directing the allergen to the lysosome, a specific compartment within the body's antigen-presenting cells. Processing the allergen through this pathway is designed to provoke a more robust and targeted T-cell immune response. For allergies, the critical goal is to shift the body's reaction away from the problematic Th2-dominant response that causes allergic symptoms and toward a non-allergenic Th1-dominant response, effectively teaching the body not to overreact.

Complementing this is the use of saRNA technology. Unlike conventional mRNA vaccines, saRNA contains instructions not only for producing the target antigen but also for replicating itself once inside a cell. This self-amplification means a much larger amount of the antigen can be produced from a very small initial dose, leading to a more potent and sustained immune stimulation. For an allergy vaccine, this sustained expression could be the key to achieving long-term immunological memory and durable tolerance, potentially with far fewer doses than traditional immunotherapy.

By marrying the targeted presentation of the UNITE® platform with the amplified expression of saRNA, ITI-9001 aims to deliver a powerful one-two punch designed to fundamentally re-educate the immune system.

From Lab to Clinic: A Story of Strategic Acceleration

The speed with which ITI-9001 moved into the clinic is a testament to the company's operational focus and the strategic vision of its parent company, HLB. Dosing the first patient just weeks after Japan's Pharmaceuticals and Medical Devices Agency (PMDA) gave the green light on June 11, 2026, demonstrates remarkable efficiency in navigating complex regulatory and logistical hurdles. This rapid execution, managed in collaboration with the Japanese contract research organization CMIC, is a strong signal of the company's commitment.

This milestone is a key part of HLB Group's broader strategy. The South Korean conglomerate acquired Immunomic Therapeutics in 2019, making a significant bet on its nucleic acid immunotherapy platforms. The progress of ITI-9001 validates that investment and strengthens ITI's position as a critical engine for HLB's expansion into biotechnology. Furthermore, this is not an isolated success. In January 2026, ITI received FDA clearance to begin trials for ITI-5000, an saRNA vaccine for triple-negative breast cancer. These parallel advancements in allergy and oncology underscore the versatility and potential of the company's core technology platforms.

"ITI-9001 is designed not merely to relieve symptoms, but to modulate the immune response and address the underlying disease," stated Dong Gun Kim, Chief Executive Officer of ITI. "Through this Phase 1 study, we look forward to establishing its safety profile and initial immunogenicity and accelerating its development as a next-generation immunotherapy for Japanese cedar pollen allergy."

The Phase 1 trial is a randomized, placebo-controlled study that will first evaluate safety across low- and high-dose cohorts to determine an optimal dose before assessing its ability to generate an immune response. Encouragingly, the first participant has completed initial monitoring with no significant safety concerns observed to date, marking a successful first step on a long but promising clinical journey.